Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
71
GLSI Quote, Financials, Valuation and Earnings
Last price:
$12.93
Seasonality move
:
-2.66%
Day range:
$11.95 - $13.10
52-week range:
$7.78 - $14.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
82.50x
Volume:
333K
Avg. volume:
252K
1-year change:
3.91%
Market cap:
$180.2M
Revenue:
--
EPS (TTM):
-$1.46
Analysts' Opinion
-
Consensus RatingGreenwich LifeSciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $45.00, Greenwich LifeSciences, Inc. has an estimated upside of 245.89% from its current price of $13.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $45.00 representing -245.89% downside risk from its current price of $13.01.
Fair Value
-
According to the consensus of 1 analyst, Greenwich LifeSciences, Inc. has 245.89% upside to fair value with a price target of $45.00 per share.
GLSI vs. S&P 500
-
Over the past 5 trading days, Greenwich LifeSciences, Inc. has overperformed the S&P 500 by 21.12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Greenwich LifeSciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Greenwich LifeSciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Greenwich LifeSciences, Inc. reported revenues of --.
Earnings Growth
-
Greenwich LifeSciences, Inc. earnings have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Greenwich LifeSciences, Inc. reported earnings per share of -$0.30.
Enterprise value:
176.4M
EV / Invested capital:
80.75x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
-20.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.7K
Return On Assets:
-496.79%
Net Income Margin (TTM):
--
Return On Equity:
-781.94%
Return On Invested Capital:
-781.94%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.6K | -$3.6K | -$2.7K | -$900 | -- | |
| Operating Income | -$9.4M | -$10.8M | -$19.6M | -$2.7M | -$4.2M | |
| EBITDA | -$9.4M | -$10.8M | -$19.6M | -$2.7M | -$4.2M | |
| Diluted EPS | -$0.70 | -$0.81 | -$1.46 | -$0.20 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $28.9M | $15.6M | $9.1M | $5.8M | $3.8M | |
| Total Assets | $28.9M | $15.6M | $9.1M | $5.8M | $3.8M | |
| Current Liabilities | $455.1K | $237.9K | $297.3K | $842.4K | $1.6M | |
| Total Liabilities | $455.1K | $237.9K | $297.3K | $842.4K | $1.6M | |
| Total Equity | $28.5M | $15.4M | $8.9M | $5M | $2.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.5M | -$7.6M | -$8.6M | -$2.6M | -$2.7M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $4.2M | $6.6M | $1.2M | $3.4M | |
| Free Cash Flow | -$6.5M | -$7.6M | -$8.6M | -$2.6M | -$2.7M | |
GLSI
Sector
Market Cap
$180.2M
$28.3M
Price % of 52-Week High
89.91%
51.3%
Dividend Yield
0%
0%
Shareholder Yield
-7.89%
-1.42%
1-Year Price Total Return
3.91%
-17.78%
Beta (5-Year)
2.924
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.12
200-day SMA
Buy
Level
$10.22
Bollinger Bands (100)
Buy
Level
8.93 - 11.73
Chaikin Money Flow
Sell
Level
-39M
20-day SMA
Buy
Level
$9.62
Relative Strength Index (RSI14)
Buy
Level
76.83
ADX Line
Buy
Level
38.54
Williams %R
Sell
Level
-19.0224
50-day SMA
Buy
Level
$9.27
MACD (12, 26)
Buy
Level
0.81
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
48.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (22.0325)
Sell
CA Score
(Annual)
Level (-11.957)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (26.3695)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Stock Forecast FAQ
In the current month, GLSI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GLSI average analyst price target in the past 3 months is $45.00.
-
Where Will Greenwich LifeSciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Greenwich LifeSciences, Inc. share price will rise to $45.00 per share over the next 12 months.
-
What Do Analysts Say About Greenwich LifeSciences, Inc.?
Analysts are divided on their view about Greenwich LifeSciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Greenwich LifeSciences, Inc. is a Sell and believe this share price will drop from its current level to $45.00.
-
What Is Greenwich LifeSciences, Inc.'s Price Target?
The price target for Greenwich LifeSciences, Inc. over the next 1-year time period is forecast to be $45.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GLSI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Greenwich LifeSciences, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of GLSI?
You can purchase shares of Greenwich LifeSciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Greenwich LifeSciences, Inc. shares.
-
What Is The Greenwich LifeSciences, Inc. Share Price Today?
Greenwich LifeSciences, Inc. was last trading at $12.93 per share. This represents the most recent stock quote for Greenwich LifeSciences, Inc.. Yesterday, Greenwich LifeSciences, Inc. closed at $13.01 per share.
-
How To Buy Greenwich LifeSciences, Inc. Stock Online?
In order to purchase Greenwich LifeSciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GLSI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GLSI
Sector
P/E ratio
--
23.99x
PEG ratio
-0.11x
-0.01x
P/B ratio
82.50x
1.80x
Price / LTM sales
--
1.59x
Growth Metrics
GLSI
Sector
Revenue growth
--
4.62%
Earnings growth
-49.88%
10.71%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.20
Profitability
GLSI
Sector
Profitability FY 2024
-$3.6K
$3.6M
Return on invested capital
-781.94%
-31.84%
Return on assets
-496.79%
-27.96%
Return on equity
-781.94%
-37.47%
Earnings Date
Last Earnings Date
Nov
17
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
16
Balance Sheet
GLSI
Sector
Total cash
$3.8M
$26.4M
Short term investments
--
$25.7M
Total assets
$4.1M
$78M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
